SCHEMBL4265183

SCHEMBL4265183

O=C1COc2ccc(-c3nc4c(s3)CCc3nonc3-4)cc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.43
POLB P06746 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
NR3C2 P08235 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
KDM4E B2RXH2 2/20 0.41
THRB P10828 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
NR2F2 P24468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259506 0.78 ALDH1A1 (0.52) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4263441 0.75 RXFP1 (0.52) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4270967 0.68 MAPT (0.55) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4262015 0.66 MMP12 (0.58) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4272682 0.65 MAPT (0.74) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4258374 0.65 POLB (0.58) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL5214057 0.65 ALDH1A1 (0.60) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4267740 0.65 POLB (0.69) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4286493 0.65 MAPT (0.58) MAPTALDH1A1HPGDKMT2APOLB
SCHEMBL4259588 0.65 POLB (0.69) MAPTALDH1A1HPGDKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 MAPT 3273/4885ALDH1A1 3483/4885HPGD 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.